A large survey study finds that most bladder cancer patients who undergo cystectomy with urinary diversion continue to face ...
Anktiva is now approved for BCG-unresponsive papillary-only bladder cancer. Here’s what the bladder-sparing option involves, ...
A retrospective study of 126 bladder cancer patients suggests that ERAS-based perioperative nursing care is associated with ...
Nogapendekin alfa inbakicept-pmln plus BCG now covers high-grade papillary-only disease, based on extrapolation from CIS ...
Morning Overview on MSN
The FDA approved Anktiva as the first treatment for one BCG-resistant form of bladder cancer
On October 14, the U.S. Food and Drug Administration announced that Anktiva (nogapendekin alfa inbakicept-pmln), used ...
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the publication of long-term data from the Phase 2/3 QUILT-3.032 study (N=100) in the Journal of Urology.
Mens Fitness on MSN
New FDA approval aims to help patients avoid bladder removal surgery
The decision gives certain patients whose cancer has resisted BCG therapy another treatment option aimed at preserving the ...
ImmunityBio (IBRX) stock fell 7.25% to $9.27 despite ANKTIVA trial results showing a 71% response rate and lasting benefits ...
American Society for Radiation Oncology (ASTRO) published its first clinical practice guideline on radiation therapy for ...
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has expanded the approved indication for ANKTIVA® ...
ImmunityBio (IBRX) Shares Drop 7.25% as Investors Overlook 71% Response Rate in Bladder Cancer Trial
ImmunityBio (IBRX) stock dropped 7.25% Friday despite ANKTIVA trial showing 71% complete response and 26.6-month median ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results